INS and diabetes mellitus: More in detail, previous research has indicated that, in particular, systemic therapy is linked to diabetes by interfering with insulin secretion (e.g., immune checkpoint inhibitors),9 reducing insulin sensitivity (e.g., mTOR inhibitors),10 or both (e.g., selective estrogen receptor modulators).11